Improving treatment of non-Hodgkin lymphoma (NHL) through pretargeted radioimmunotherapy (PT-RIT) and consolidation veltuzumab (humanized anti-CD20) IgG serotherapy

被引：0
|
作者：
Sharkey, R. M. [1 ,2 ]
Karacay, H. [1 ,2 ]
Johnson, C. R. [1 ,2 ]
Rossi, E. A. [3 ]
McBride, W. J. [4 ]
Chang, C-H [3 ,4 ]
Goldenberg, D. M. [1 ,2 ,3 ,4 ]
机构：
[1] Ctr Mol Med & Immunol, Belleville, NJ USA
[2] Garden State Canc Ctr, Belleville, NJ USA
[3] IBC Pharmaceut Inc, Morris Plains, NJ USA
[4] Immunomedics Inc, Morris Plains, NJ USA
来源：
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS | 2008年 / 23卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
26
引用
收藏
页码：521 / 521
页数：1
相关论文
共 50 条
  • [1] Combination anti-CD20 immunotherapy and pretargeted anti-CD20 radioimmunotherapy (PT-RAIT) of non-Hodgkin lymphoma (NHL) shows improved efficacy
    Goldenberg, David M.
    Karacay, Habibe
    Chang, Chien-Hsing
    Rossi, Edmund A.
    McBride, William J.
    Sharkey, Robert M.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [2] Pretarget radioimmunotherapy (RIT) with anti-CD20 fusion protein in patients with non-Hodgkin's lymphoma (NHL).
    Meredith, R
    Shen, S
    Breitz, H
    Fisher, D
    Goris, M
    Knox, S
    Hankins, J
    Vose, J
    Picozzi, V
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 116P - 117P
  • [3] Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
    Sharkey, Robert M.
    Karacay, Habibe
    Johnson, Christine R.
    Litwin, Samuel
    Rossi, Edmund A.
    McBride, Williarn J.
    Chang, Chien-Hsing
    Goldenbero, David M.
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (03) : 444 - 453
  • [4] Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL)
    Weiden, PL
    Breitz, HB
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (01) : 37 - 51
  • [5] Radioimmunotherapy (RIT) of non-Hodgkin's lymphoma (NHL) with I-131 anti-CD20 monoclonal antibody (Bexxar™).: Preliminary results
    Antonescu, C
    Buchegger, F
    Kosinski, M
    Ketterer, N
    Kovacsovics, T
    Helg, C
    Delaloye, AB
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 980 - 980
  • [6] Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
    Morschhauser, Franck
    Leonard, John P.
    Fayad, Luis
    Coiffier, Bertrand
    Petillon, Marie-Odile
    Coleman, Morton
    Schuster, Stephen J.
    Dyer, Martin J. S.
    Horne, Heather
    Teoh, Nick
    Wegener, William A.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3346 - 3353
  • [7] Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
    Sharkey, Robert M.
    Karacay, Habibe
    Litwin, Samuel
    Rossi, Edmund A.
    McBride, William J.
    Chang, Chien-Hsing
    Goldenberg, David M.
    CANCER RESEARCH, 2008, 68 (13) : 5282 - 5290
  • [8] Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Forero, A
    Weiden, PL
    Vose, JM
    Knox, SJ
    LoBuglio, AF
    Hankins, J
    Goris, ML
    Picozzi, VJ
    Axworthy, DB
    Breitz, HB
    Sims, RB
    Ghalie, RG
    Shen, S
    Meredith, RF
    BLOOD, 2004, 104 (01) : 227 - 236
  • [9] Pretargeted radioimmunotherapy (PRITR) for treatment of non-Hodgkin's lymphoma (NHL):: Preliminary results.
    Breitz, HB
    Wieden, PL
    Appelbaum, JW
    Stone, DM
    Axworthy, DB
    Fisher, DR
    Press, O
    Abrams, PG
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 19P - 19P
  • [10] Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura
    Milani, Cannon
    Castillo, Jorge
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2009, 11 (02) : 200 - 207
12345